What OM1 does

OM1 is a Boston-based, privately held healthcare technology company founded in 2015 by Dr. Rich Gliklich that operates a vertically integrated AI platform for generating regulatory-grade real-world evidence (RWE). Its core technology is the patented PhenOM® foundation model — trained on over 1 billion patient-years of longitudinal data spanning 350M+ patients, 1.8M providers, and 90% claims linkage — paired with an Agentic Health Data Framework that uses LLMs, NLP, and machine learning to automate data capture, processing, and enrichment across structured and unstructured EMR, claims, labs, patient-reported outcomes, and social determinants of health. The platform has produced nine validated AI-extracted clinical endpoints (e.g., ePHQ-9, eCDAI, eSLEDAI) used in successful FDA submissions, including the largest AI-processed RWE study supporting Hologic's Aptima HPV Assay label expansion in February 2026.

The company's commercial model combines subscription-based licensing of its Real-World Data Cloud and PhenOM API, usage-based AI prediction services, fee-based clinical registries and automated studies (300+ delivered), and professional scientific/consulting services. OM1 serves three primary customer segments: life sciences companies (Amgen, Abbvie, GSK, Johnson & Johnson, Novartis, Hologic), providers and health systems, and payers — with a quote-based enterprise sales motion supplemented by an API-first distribution channel and European operations led from Switzerland. Its 130+ peer-reviewed publications, 10+ AI patents, and authorship of AHRQ's Registries for Evaluating Patient Outcomes reference text create defensible differentiation in a market competing with Aetion, Flatiron/Roche, IQVIA, and PAREXEL.

Name

OM1

Legal name

OM1, Inc.

Website

https://om1.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

101–250 employees

Short description

OM1 is a Boston-based healthcare AI company that runs the PhenOM® foundation model on 1B+ patient-years of real-world data to deliver regulatory-grade evidence, patient finding, and AI-extracted clinical endpoints to life sciences companies, providers, and payers.

Ownership category

akta.pro rank

Product category

Healthcare Real-World Evidence Analytics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Software Publishers (5132)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Prepackaged Software (7372)

akta.pro primary industry

Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF)

akta.pro secondary industry

Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)

Keywords

• Real-world evidence
• Healthcare AI platform
• Clinical data analytics
• Patient outcomes prediction
• Clinical registry software

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Enterprise Platform Subscriptions / Data Licensing: Recurring access to OM1's Real-World Data Cloud (350M+ patients), curated datasets, PhenOM API, and AI platform for life sciences, providers, and payers. Customers license cohorts and use the platform for ongoing evidence generation.
2. Clinical Registries and Automated Studies: Fee-based prospective and retrospective study programs, including product/disease registries, post-approval safety/effectiveness studies (PASS/PAES), long-term follow-up, and rare disease programs; delivered via 300+ registry/study engagements.
3. Scientific & Consulting Services: Project-based RWE studies, rapid insights/feasibility analytics, and regulatory and payer strategy consulting delivered by OM1's in-house epidemiologists, biostatisticians, and data scientists.
4. Patient Finding and Outcomes Prediction (PhenOM API): API-driven delivery of patient finding, subtyping, medical events prediction, and treatment response predictions; 200,000 predictions available with results deliverable via API, applications, EHR integration, or reports.
5. Data Monetization / Cohorts: License of curated, AI-enriched disease-area and custom cohorts (e.g., Alzheimer's, Depression, Heart Failure, Psoriasis) from the OM1 Real-World Data Cloud with linked EMR, claims, and specialty network data.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels9 records

Core offering

OM1 builds and operates an AI-powered real-world evidence platform centered on its patented PhenOM® foundation model, trained on over 1 billion patient-years of linked clinical data. The company sells access to its Real-World Data Cloud (350M+ patients), AI-driven patient finding and outcomes prediction, automated clinical registries, curated disease datasets, and scientific consulting services to life sciences companies, healthcare providers, and payers.

Product overview

OM1 is a platform-plus-modules architecture centered on its patented PhenOM® Foundation Model (trained on over 1 billion patient-years of healthcare data) and the Agentic Health Data Framework. Together, these power OM1's solution modules: (1) Patient Finding & Outcomes Prediction for digital phenotyping and predictive analytics; (2) Clinical Registries and Automated Studies covering 300+ registries with agentic data collection, including PASS/PAES, LTFU, and rare disease programs; (3) Clinical Datasets & Insights backed by the OM1 Real-World Data Cloud (350M+ patients, 90% linked to claims); and (4) Scientific & Consulting Services supported by the Registry Center of Excellence. The PhenOM API exposes these capabilities for partner and developer use. Specialized applications include the Joint Insights™ AI decision support tool (co-developed with Dell Medical School) and the OM1 Patient Finder for rare disease identification. All products leverage OM1's validated NLP/LLM extraction and AI-estimated clinical endpoints (e.g., ePHQ-9, eCDAI, eSLEDAI) used in successful regulatory submissions.

Differentiator

Problem solved

Functional benefit

Brands

• PhenOM®: OM1's patented AI foundation model for healthcare, trained on over 1 billion patient-years, used for digital phenotyping, subtyping, and prediction of medical events, risks, and treatment outcomes.
• Joint Insights™
• OM1 Patient Finder
• OM1 Real-World Data Cloud
• OM1 Registry Center of Excellence
• PremiOM™

Products and services

• PhenOM® Foundation Model Patented AI foundation model trained on 1B+ patient-years of real-world healthcare data, used for digital phenotyping, subtyping, patient finding, and prediction of medical events, risks, and treatment outcomes. Sold as a licensed AI platform to life sciences companies, providers, and payers.
• Agentic Health Data Framework Automation framework that orchestrates AI agents to capture, process, and enrich real-world clinical data, supporting faster and more reliable study execution, registry data collection, and dataset enrichment.
• Patient Finding and Outcomes Prediction Solution module built on PhenOM® that accelerates patient finding for undiagnosed conditions, predicts disease progression and adverse events, estimates treatment response, and forecasts outcomes. Includes Patient Finding, Subtyping & Segmentation, Medical Events & Outcomes Prediction, and Treatment Response capabilities.
• Clinical Registries and Automated Studies Solution module delivering 300+ registries and observational studies with agentic data collection and processing, including product/disease registries, post-approval safety/effectiveness studies (PASS/PAES), long-term follow-up, and rare disease programs.
• Clinical Datasets and Insights Curated, AI-enriched clinical and real-world datasets covering 350M+ patients with 10-year median follow-up, integrating structured and unstructured data (EMR, clinical notes, claims, labs, PROs, social determinants). Includes disease-area datasets and Cohort Explorer dashboards licensed to customers.
• Scientific and Consulting Services Expert consulting in data science, epidemiology, AI, and regulatory strategy, including RWE Studies, Rapid Insights analytics, and Regulatory and Payer Strategy services, supported by 130+ publications across 10+ therapeutic areas.
• Joint Insights™ AI-powered clinical decision support tool co-developed with Dell Medical School, powered by PhenOM®, that improves treatment decision quality and patient outcomes for knee osteoarthritis patients.
• OM1 Patient Finder Proprietary AI tool that identifies patterns in medical histories signaling undiagnosed disease, including rare disease identification. Achieved AUC of 0.82 in case studies with 20x positive patients in the riskiest 1% of the population.
• OM1 Real-World Data Cloud Cloud-based real-world data platform covering 350M+ patients with 90% linked to claims, 1.8M providers represented, and 10-year median follow-up. HIPAA-compliant, de-identified datasets licensed for AI model training, validation, and evidence generation.
• OM1 Registry Center of Excellence Strategic consultation, scientific oversight, and data quality expertise for the design, planning, and execution of registry and prospective observational study programs, led by senior editors of AHRQ's Registries for Evaluating Patient Outcomes.

Named customers15 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature8 records

Partnerships

Six partnerships are on record, tiered core and flagship.

• Dell Medical School (The University of Texas at Austin)coreStrategic or Co-development Partner · 10 December 2025Co-developed Joint Insights™, an AI-powered decision support tool for knee osteoarthritis. A Lancet-published clinical trial demonstrated improved treatment decision quality and patient outcomes; the work builds on the earlier JAMA Network Open RCT (2021).
• HologicflagshipStrategic or Co-development Partner · 1 January 2018Long-term strategic collaboration: Hologic partnered with OM1 to develop a large-scale, automated patient registry for digital breast tomosynthesis vs. digital mammography screening (1.1M women enrolled, 2.5M screenings, 5 large U.S. health systems, 63 imaging facilities). Joint work extended to support FDA approval of Hologic's Aptima HPV Assay in February 2026 based on 650,000+ patient real-world evidence study using OM1's AI platform.
• NovartiscoreStrategic or Co-development PartnerPartnered with the American Academy of Dermatology (AAD) and OM1 to use PhenOM® AI to enhance diagnosis and treatment for patients with hidradenitis suppurativa (HS).
• American Academy of Dermatology (AAD)coreStrategic or Co-development PartnerPartnered with Novartis and OM1 to use PhenOM® AI to enhance diagnosis and treatment for hidradenitis suppurativa patients.
• 30+ Centers of Excellence (GPP)coreImplementation/ SI/ Consulting PartnerMulti-center prospective study in Generalized Pustular Psoriasis (GPP) engaging 30+ Centers of Excellence and 'referral-only sites' over 3 years, with an OM1 central site responsible for clinical outcomes assessments.
• 5 Large U.S. Health Systems (breast cancer screening)coreTechnology or IntegrationPartner health systems and 63 imaging facilities provided EMR, radiology information systems, and tumor registry data integrated into OM1's common data model for the breast cancer screening registry with Hologic.

Scale indicators14 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• IQVIA: Largest global RWE, clinical research, and healthcare data analytics provider. Comparable to OM1 as a buyer and operator of large-scale real-world data, registries, and post-approval studies, but with materially broader scale and a non-AI-native stack.
• Veradigm (formerly Allscripts): Healthcare data and analytics provider built on top of large EHR installed base, including life sciences research-grade datasets. Overlaps with OM1's Real-World Data Cloud and clinical datasets offering for life sciences and providers.
• Optum (UnitedHealth Group): Largest US healthcare data and analytics franchise, integrating claims, EHR, and pharmacy data. Comparable to OM1 on real-world data scale and payer/provider analytics, but with vastly broader assets and a non-API-first commercial model.
• ICON plc: Global CRO and RWE services provider following the PRA Health Sciences merger. Comparable to OM1 in registries, post-marketing studies, and RWE consulting for life sciences, with broader clinical operations scale.
• Medidata Solutions (Dassault Systèmes): Clinical trials and real-world data platform for life sciences, with synthetic control arms and RWE analytics. Overlaps with OM1's automated studies and AI-driven evidence generation, particularly in clinical development.

Direct peers

• Aetion: Real-world evidence analytics platform serving life sciences with regulatory-grade evidence generation for market access and safety. Direct peer to OM1's life sciences RWE offering, with comparable enterprise GTM and FDA-facing positioning.
• Flatiron Health: Oncology-focused real-world data and clinical research platform acquired by Roche. Highly comparable to OM1's disease-specific AI data and registry capabilities, with deep regulatory and pharma partnerships.
• Tempus AI: AI-driven precision medicine company combining multi-modal clinical and molecular data for life sciences and providers. Comparable to OM1 on the AI foundation model plus healthcare data cloud thesis, with overlap in life sciences and clinical decision support.

Emerging players

• ConcertAI: AI SaaS company for oncology RWE and clinical research, with curated real-world data and AI applications for pharma. Comparable to OM1's specialty RWE and AI decision support offerings in oncology and adjacent therapeutic areas.
• Datavant: Health data connectivity and de-identification layer enabling linkage across data sources. Comparable to OM1's linked EMR/claims/specialty network data cloud and supports similar life sciences and provider use cases.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/om1inc
• LinkedInlinkedin.com/company/om1-inc.

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries1 record

Funding overview

Funding rounds4 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OM1